BWA
ENTA icon

BDO Wealth Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

BDO Wealth Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-20
Closed -$1K – 894
2020
Q2 		$1K Hold
20
– – ﹤0.01% 652
2020
Q1 		$1K Buy
+20
New +$1.07K ﹤0.01% 700

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BDO Wealth Advisors's ENTA Position: Q3 2020 in Review

BDO Wealth Advisors sold out of Enanta Pharmaceuticals (ENTA) in Q3 2020, closing a stake of 20 shares — an estimated $1K sold.

BDO Wealth Advisors first reported a position in ENTA in Q1 2020 and held it in 2 quarters. The position peaked at $1K in Q2 2020. 172 funds tracked by Wall St. Rank hold ENTA as of Q3 2020.

  • BDO Wealth Advisors reported no remaining Enanta Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • BDO Wealth Advisors sold 20 Enanta Pharmaceuticals shares in Q3 2020, an estimated $1K.
  • BDO Wealth Advisors first reported a position in Enanta Pharmaceuticals in Q1 2020 and held it in 2 quarters.
  • BDO Wealth Advisors's Enanta Pharmaceuticals position peaked at $1K in Q2 2020.
  • 172 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2020.

Based on BDO Wealth Advisors's 13F filing for Q3 2020, filed 12 Nov 2020.